An interventional study of Urine bacterial Culture (UC) and No intervention before TURB surgery in Bladder Cancer, Transurethral Resection of the Bladder and Urinary Tract Infection Bacterial, sponsored by Poitiers University Hospital. Recruiting at 15 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Other
Among 160 studies in Urinary Bladder Neoplasms with a site in France — 40 open to participants now, 62 under way, 15 of them phase 3. Urinary Bladder Neoplasms · France.
Among the 160 studies in Urinary Bladder Neoplasms with a site in France, this one has the largest planned enrollment of the 129 interventional ones that give a count, is one of 8 that started in 2026, is one of 17 with no phase, reaches primary completion later than 55 of the 61 other live ones, and was the 156th registered.
1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →40 of the 160 studies in Urinary Bladder Neoplasms with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Australia and 13 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Merck Sharp & Dohme LLC · Sites in France, United States, Argentina and 14 more countries
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in France, United States, Australia and 9 more countries
Ages 18+
Institut du Cancer de Montpellier - Val d'Aurelle · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 61 · Phase 3 30 · Phase 4 1
First in 1997; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,600 is above the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 169 across the 129 interventional studies, 293 across the 29 observational. Of the 94 that completed or were terminated, 40 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 160 have an industry lead sponsor. The 10 most frequent:
Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.
Poitiers University Hospital has 1 study filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
21 of the studies in Urinary Bladder Neoplasms with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04658862Phase 3Janssen Research & Development, LLCA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | 2026-12-30 |
| NCT05911295Phase 3Seagen, a wholly owned subsidiary of PfizerDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | 2027-01-29 |
| NCT04241185Phase 3Merck Sharp & Dohme LLCEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | 2027-01-31 |
| NCT05544552Tyra Biosciences, IncSafety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | 2026-11 |
| NCT03915678Institut BergoniéAtezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | 2026-12 |
Add all 21 to your calendar (.ics) → With an account.
Among the 160 studies in Urinary Bladder Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to demonstrate that not performing a systematic UC before the TURB procedure is non-inferior to performing a systematic UC in terms of the incidence of febrile UTIs during the first 30 postoperative days
Transurethral resection of the bladder (TURB) is a routinely performed surgery in urology (65,000/y in France). Its primary indication is the management of bladder cancer for diagnostic, prognostic, and therapeutic purposes. Currently, both French and European guidelines recommend screening for asymptomatic bacteriuria (ABU) using a urine culture (UC) before TURB. If the UC is positive, antibiotic treatment must be initiated 48 hours before surgery and continued for a maximum of 7 days after the procedure. Theoretically, the purpose of preoperative ABU screening before TURB is to reduce the rate of post-operative urinary tract infections (UTIs). However, there is currently a lack of high-level studies justifying this approach, despite its being a recommended practice. The literature estimates the rate of post-TURB UTIs to be between 2% and 3.7%. In a recent French multicentre retrospective study, the rate of postoperative febrile UTI was 2.3%. This study did not find a significant association between positive pre-operative UC and a post-operative febrile UTI. Moreover, these post-TURB infections are generally of moderate severity (Grade 2 of Clavien-Dindo classification) and do not progress to sepsis. The rate of severe infections is estimated between 0.3% and 0.74%, and no study has yet demonstrated the link between the presence of a positive preoperative UC and an increased risk of postoperative infection. The causality between preoperative UC and postoperative UTIs remains unestablished. According to the TOCUS study, approximately one-third of patients exhibit ABU before undergoing urological surgery, translating to approximately 20,000 patients annually in France. Despite the relatively low rate of post-TURB UTIs and their mild severity, guidelines mandate antibiotic treatment for these patients. Antibiotic resistance is now a daily concern for clinicians and countries alike. A prominent 2014 WHO report emphasized the consequences of antibiotic resistance, including its impact on morbidity, mortality, and societal costs. The risk of entering a post-antibiotic era by 2050 could become a reality if strong measures are not taken immediately. Therefore, we propose a non- inferiority randomized controlled trial to investigate the impact of not performing pre-operative UC before TURB on the incidence of post-TURB febrile UTIs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: No intervention before TURB surgery
Diagnostic Test: Urine bacterial Culture (UC)
Performing a systematic UC before the TURB surgery
No Urine Culture before TURB Surgery
Proportion of patients with post-TURB symptomatic febrile Urinary Tract Infection (UTI)
The diagnosis of a febrile UTI will be based on clinical, biological and microbiological criteria, as defined by Bilsen et al. based on an international expert consensus (PMID: 38458204)
Time frame: During the 30 days following TURB surgery.
Proportion of patients with postponed TURB surgery
Time frame: Between the pre-operative consultation and date of TURB surgery, up to 60 days
Time to surgery
time to surgery (in days) is defined as the number of days between the pre-operative consultation and the date of TURB surgery
Time frame: Between the pre-operative consultation and the date of TURB surgery, up to 60 days
The hospital length of stay
The hospital length of stay , defined by the number of days between surgery and discharge from the hospital
Time frame: Between TURB surgery and day 30 after TURB surgery
Proportion of patients with hospital readmission or postoperative complications
Time frame: Within 30 days following the TURB surgery
Proportion of patients with hospital readmission linked to the urinary surgical procedure
Time frame: Within 30 days following the TURB surgery
Proportion of patients with systemic UTI among patients with hospital readmission
Systemic UTI is defined as UTI complicated by sepsis (corresponding to a qSOFA \> 1)
Time frame: Within 30 days following the TURB surgery
Proportion of patients with pre-operative antibiotic prescription for preoperative colonization before the TURB surgery
Time frame: Between Visit 0 (pre-operative consultation) and Visit 1(TURB surgery)
Proportion of patients with post-operative antibiotic prescription
Time frame: Within 30 days following the TURB surgery
Time to post-TURB infection diagnosis
Time to post-TURB infection diagnosis (in days), defined by the time between TURB surgery and the infection diagnosis date (truncated at day 30)
Time frame: Between the TURB surgery and the infection diagnosis date (truncated at day 30)
Overall survival time
Overall survival time (in days), defined by the time between TURB surgery and the date of death (censored at day 30).
Time frame: Between TURB surgery and the date of death (censored at day 30)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Jul 2030, 49 months after the start.
Of 235 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 70. This study's planned 49 months is above that.
Counting every sponsor, half of 244 studies reached it within 39 months; a quarter within 20 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →